Visterra Closes $30 Million Series B Financing to Advance Pipeline of Multiple Products for Infectious Diseases

Visterra Closes $30 Million Series B Financing to Advance Pipeline of Multiple Products for Infectious Diseases

October 2, 2014

 – Co-led by New Investors, Merck Research Labs Venture Fund, Vertex Venture Holdings and Temasek –

Eleven Biotherapeutics Announces Top-Line Results from Phase 2 Study of EBI-005 in Patients with Moderate to Severe Allergic Conjunctivitis

Eleven Biotherapeutics Announces Top-Line Results from Phase 2 Study of EBI-005 in Patients with Moderate to Severe Allergic Conjunctivitis

October 2, 2014

 - EBI-005 Demonstrated Statistically Significant Improvements in Ocular Itching, Tearing and Nasal Symptoms in a Conjunctival Allergen Provocation Model -

- Study Does Not Meet Primary Endpoint Using Environmental Exposure Chamber Model -

Avedro Announces Resubmission of New Drug Application to FDA for Corneal Cross-Linking

Avedro Announces Resubmission of New Drug Application to FDA for Corneal Cross-Linking

September 30, 2014

Waltham, Massachusetts, -- Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company announces today that it resubmitted its New Drug Application (NDA) for riboflavin ophthalmic solution/KXL® System to the U.S. Food and Drug Administration (FDA). Avedro anticipates an application action date (PDUFA) in March 2015. This resubmission is a comprehensive reply to questions and requests from the March 2014 complete response letter.

Agios Pharmaceuticals to Present Clinical Data from AG-120 Ongoing Phase 1 Study in Hematologic Malignancies at EORTC-NCI-AACR 2014

Agios Pharmaceuticals to Present Clinical Data from AG-120 Ongoing Phase 1 Study in Hematologic Malignancies at EORTC-NCI-AACR 2014

September 26, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 26, 2014-- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that clinical data from a Phase 1 study of AG-120, an orally available, selective, potent inhibitor of the mutated IDH1 protein, will be highlighted in a late breaking oral presentation at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place November 18 - 21, 2014, in Barcelona, Spain.

Syros Pharmaceuticals Presents Research on Gene Control in Acute Myeloid Leukemia at AACR Hematologic Malignancies Meeting

Syros Pharmaceuticals Presents Research on Gene Control in Acute Myeloid Leukemia at AACR Hematologic Malignancies Meeting

September 23, 2014

 - Data Indicate that Syros’ Leading Gene Control Platform Can Uncover Cancer Drivers and New Target Opportunities for Potential Treatments -

T2 Biosystems Receives FDA Authorization to Market T2Candida and T2Dx for the Detection of Sepsis-Causing Pathogens

T2 Biosystems Receives FDA Authorization to Market T2Candida and T2Dx for the Detection of Sepsis-Causing Pathogens

September 22, 2014

– Novel test to identify Candida, one of the most lethal forms of common bloodstream infections that cause sepsis, faster than current methods – hours instead of days –

– More than 10 million people tested for Candida every year –

Seres Health Named a "Fierce 15" Biotech Company for 2014

Seres Health Named a "Fierce 15" Biotech Company for 2014

September 22, 2014

CAMBRIDGE, Mass., Sept. 22, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced that it has been named by FierceBiotech as one of 2014's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.

FierceBiotech names Editas Medicine as one of its “Fierce 15” Biotech Companies of 2014

FierceBiotech names Editas Medicine as one of its “Fierce 15” Biotech Companies of 2014

September 22, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Editas Medicine today announced that it has been named by FierceBiotech as one of 2014’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.

Joule to Team with DNV GL for Commercial Validation of Transformative CO2-to-Fuels Production Process

Joule to Team with DNV GL for Commercial Validation of Transformative CO2-to-Fuels Production Process

September 17, 2014

Bedford, MA, USA – September 17, 2014 – Joule, the pioneer of direct, solar conversion of CO2 to liquid fuels, today announced that it has entered into a memorandum of understanding (MoU) with DNV GL, a leading provider of technical assurance and advisory services to the energy industry. The next step will be to define the specific areas of collaboration that will accelerate the global production of CO2-neutral fuels.

Dr. Mark Roskey Joins Quanterix Leadership Team

Dr. Mark Roskey Joins Quanterix Leadership Team

September 16, 2014

LEXINGTON, Mass.--(BUSINESS WIRE)--